Newsroom

June 2017

• 
  Story Jun 23, 2017 Patient Perspectives

  From nurse to patient: facing an aggressive blood cancer

  After being diagnosed with an aggressive form of leukemia, Ilana Massi defied the odds with the help of her friends and family.

• Press release Jun 23, 2017

  Novartis Kisqali® (ribociclib) receives positive CHMP opinion as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor

  CHMP opinion based on pivotal Phase III trial that showed Kisqali plus letrozole reduced risk of disease progression or death by 44% over letrozole alone among postmenopausal women with HR+/HER2-…
• Press release Jun 23, 2017

  Novartis data shows half of eligible Ph+ CML-CP patients remain in Treatment-free Remission nearly two years after stopping Tasigna®

  New 96-week data support durability and safety of Treatment-free Remission (TFR) in Ph+ CML-CP patients who stop taking Tasigna [1,2] More than 90% of Ph+ CML-CP patients in ENESTfreedom and ENESTop…
• Press release Jun 23, 2017

  Novartis pivotal CTL019 6-month follow-up data show durable remission rates in children, young adults with r/r B-cell ALL

  83% of patients achieved complete remission (CR) or CR with incomplete blood count recovery within 3 months of treatment with CTL019; consistent with interim ELIANA data   Data evaluating 63…
• Press release Jun 22, 2017

  Novartis combination targeted therapy Tafinlar® + Mekinist® receives FDA approval for BRAF V600E mutant metastatic non-small cell lung cancer (NSCLC)

  Approval provides first targeted treatment in the US specifically for BRAF V600E mutation-positive metastatic NSCLC   More than 60% of treatment-naïve and previously treated patients with…
• Featured News Jun 22, 2017

  Asthma and exercise: why patients can and should stay active

• Press release Jun 22, 2017

  Novartis Phase III study shows ACZ885 (canakinumab) reduces cardiovascular risk in people who survived a heart attack

  Phase III CANTOS study met the primary endpoint, a composite of heart attack, stroke and cardiovascular death, showing that ACZ885 (canakinumab) in combination with standard of care therapy reduces…
• Press release Jun 21, 2017

  Novartis achieves important regulatory milestone for AMG 334 (erenumab) in migraine prevention with EMA filing acceptance

  AMG 334 (erenumab) is the first anti-CGRP monoclonal antibody developed for migraine prevention to receive EMA regulatory filing acceptance   Filing is supported by a comprehensive clinical…
• 
  Story Jun 20, 2017 Access to Healthcare

  Helping Syrian refugees manage chronic diseases

  Among the many Syrians uprooted by armed conflict are thousands of people with chronic conditions – such as diabetes and heart disease - whose treatment was disrupted when they fled.

• Press release Jun 20, 2017

  Novartis RTH258 (brolucizumab) demonstrates robust visual gains in nAMD patients with a majority on a 12-week injection interval

  RTH258 achieved the primary efficacy endpoint of non-inferiority to aflibercept in mean change in BCVA from baseline to week 48[1],[2] in two head-to-head pivotal Phase III studies[3],[4]…
• Press release Jun 20, 2017

  Novartis real world study shows almost half of chronic urticaria patients are not receiving any treatment despite significant disease burden

  Urgent need to improve management of chronic urticaria (CU) - a disease that causes itchy, persistent hives and swelling which last more than 6 weeks or recur over months or years - highlighted by…
• Press release Jun 19, 2017

  Sandoz receives approval in Europe for Rixathon® (biosimilar rituximab) to treat blood cancers and immunological diseases

  European Commission approves Sandoz Rixathon® to treat blood cancers and immunological diseases. Approval expected to broaden patient access to biologics and enable budget-constrained healthcare…